Study #2022-0492
PET adapted Brentuximab Vedotin and Pembrolizumab in combination with Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab, Dacarbazine
Description
To learn about the effects of brentuximab vedotin and pembrolizumab in combination with doxorubicin and dacarbazine when given to patients who have Stage II cHL with bulky mediastinal disease or advanced cHL (Stage III or IV) and who have not received treatment for the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hodgkin Lymphoma
Study phase:
Phase II
Physician name:
Hun Ju Lee
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-833-997-0212
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.